Search Results

You are looking at 41 - 50 of 96 items for :

  • Refine by Access: Content accessible to me x
Clear All

subscales. The MEQ-30 has demonstrated sensitivity in assessing the effects of a range of psychedelic compounds, including LSD ( Schmid & Liechti, 2018 ), MDMA ( Lyvers & Meester, 2012 ), psilocybin ( Barrett et al., 2015 ), ayahuasca ( Schenberg, Tofoli

Open access

, DMT, and other substances, as seen in Table 1 . Table 1. Lifetime use of hallucinogens Hallucinogen Mean (SD) Median Range LSD 27.51 (104.99) 1.00 0–1,000 Mushrooms 25.64 (94.08) 5.00 0–1,000 MDMA 19.55 (82.7) 0.00 0–5 DMT 3.66 (11.21) 0.00 0

Open access
Journal of Psychedelic Studies
Authors:
Thaddeus James Camlin
,
Donald Eulert
,
Arthur Thomas Horvath
,
Steven F. Bucky
,
Joseph P. Barsuglia
, and
Martin Polanco

( Depoortere, 1987 ; Marrosu et al., 1995 ; Schneider & Sigg, 1957 ). If an ibogaine protocol is developed and psychotherapy is a part of it, as it is in the MDMA research protocol ( Mithoefer, 2017 ), then it may be worth considering the inclusion of

Open access

, M. T. , Reed , S. , & Aggarwal , R. ( 2020 ). Culturally-informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder . Journal of Psychedelic Studies , 4 ( 1 ), 40 – 50 . https://doi.org/10

Open access

general public [Bachelor's thesis, University of Twente] . http://purl.utwente.nl/essays/82465 . Therapeutic Goods Administration ( 2023 , Feb 3). Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

Open access
Journal of Psychedelic Studies
Authors:
Sam Elias
,
Stephanie Spivak
,
Alexa Alverez
,
Alejandro Gili Olivares
,
Maria Ferrol
, and
Julian Paul Keenan

, K. H. , Heifets , B. D. , Hibicke , M. , Mitchell , J. , et al. ( 2021 ). Hallucinogens in mental health: Preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine . The Journal of Neuroscience: The Official Journal of the

Open access
Journal of Psychedelic Studies
Authors:
Neşe Devenot
,
Brian A. Pace
,
Jason Slot
, and
Alan K. Davis

of harm in clinical trials of MDMA. The stakes of adequately communicating these risks to patients is high, especially since P-AT is anticipated as a treatment option for PTSD, which disproportionately impacts historically marginalized groups with

Open access

-schedule psilocybin and MDMA, allowing prescriptions by “authorised psychiatrists” for specific indications (PTSD and treatment-resistant depression, respectively) as of July 1, after an “aggressive” lobbying campaign led by Mind Medicine Australia (MMA) ( Blau

Open access

), lifetime phencyclidine (PCP) use (variable PCPFLAG; 0 = never used, 1 = ever used), lifetime 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) use (variable ECSFLAG for 2013–2014 and ECSTMOFLAG for 2015–2019; 0 = never used, 1 = ever used), and lifetime

Open access

studies showing no benefit and greater discontinuation rates (30%) compared to placebo (17%), hypothesized to be secondary to unreported adverse effects ( Friedman et al., 2007 ). Given these limitations, novel therapeutics, such as MDMA

Open access